News Medical on MSN2d
FXR cyclic peptide antagonists as a novel strategy for MASH treatment
In this study, the authors first used an AlphaScreen assay to identify a series of tryptophan-based cyclic peptide compounds with FXR-antagonistic activity, specifically those modified with a ...
Yahoo Finance20d
Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
“We are excited to deliver FXR314 and our FXR program to Lilly for Phase 2 and further development. Their world-class development excellence and dedication to delivering for patients will ...
FierceBiotech19d
Eli Lilly buys Organovo's FXR program for $10M, sending biotech's stock skyrocketing 244%
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a deal worth up to $50 million in biobucks. Organovo’s stock ...
Nasdaq19d
Organovo Holdings, Inc. Announces Acquisition of FXR Program by Eli Lilly and Company
Organovo Holdings, Inc. announced that it will be acquired by Eli Lilly and Company, which includes Organovo's FXR program and its lead asset, FXR314, aimed at treating inflammatory bowel disease ...